Skip to main content

Advertisement

Table 2 Lesion response to treatment according to pathogeny

From: Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

  Ischemic Non-ischemic Total
Complete granulation 486/790 905/1044 1392/1835
  % 61.5 86.7 75.9
  (95% CI) (58.1; 64.9) (84.6; 88.7) (73.9; 77.8)
Weeks to complete granulation median (95% CI) 6 (5.6; 6.3) 4 (3.8; 4.2) 5 (4.8; 5.2)
Healing 371/742 641/916 1012/1659
  Evaluated (“per protocol”) % 50.0 69.9 61.0
  (95% CI) (48.1; 54.9) (66.9; 73.3) (58.2; 62.9)
  Included (“intention-to-treat”) % 47.0 61.4 55.1
  (95% CI) (43.4; 50.4) (58.4; 64.4) (52.9; 57.4)
Relapses: (years-person of follow- up) 26/333 (561) 49/584 (927) 75/917 (1488)
  Rate per year (95% CI) 4.6 (2.9; 6.4) 5.3 (3.8; 6.7) 5.0 (3.9; 6.2)
Amputations during treatment 180/790 40/1044 220/1835
  % 22.8 3.8 12.0
  (95% CI) (19.9; 25.7) (2.7; 5.0) (10.5; 13.5)